Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

RXRX | Recursion Pharmaceuticals Inc

Index	RUT	P/E	-	EPS (ttm)	-1.38	Insider Own	34.92%	Shs Outstand	183.21M	Perf Week	-3.41%
Market Cap	1.62B	Forward P/E	-	EPS next Y	-1.65	Insider Trans	-1.33%	Shs Float	137.76M	Perf Month	-13.07%
Income	-259.99M	PEG	-	EPS next Q	-0.39	Inst Own	52.15%	Short Float / Ratio	17.66% / 3.69	Perf Quarter	2.41%
Sales	49.99M	P/S	32.39	EPS this Y	-7.68%	Inst Trans	5.05%	Short Interest	24.34M	Perf Half Y	18.60%
Book/sh	2.31	P/B	3.31	EPS next Y	-12.54%	ROA	-38.83%	Target Price	14.00	Perf Year	-34.39%
Cash/sh	1.93	P/C	3.96	EPS next 5Y	12.00%	ROE	-57.36%	52W Range	4.54 - 16.75	Perf YTD	-0.78%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-50.39%	52W High	-54.31%	Beta	0.01
Dividend %	-	Quick Ratio	3.72	Sales past 5Y	173.07%	Gross Margin	-0.14%	52W Low	68.50%	ATR	0.51
Employees	-	Current Ratio	3.72	Sales Q/Q	43.56%	Oper. Margin	-550.41%	RSI (14)	36.01	Volatility	4.25% 5.13%
Optionable	Yes	Debt/Eq	0.11	EPS Q/Q	-0.05%	Profit Margin	-520.12%	Rel Volume	0.31	Prev Close	7.77
Shortable	Yes	LT Debt/Eq	0.10	Earnings	Aug 08 BMO	Payout	-	Avg Volume	6.59M	Price	7.65
Recom	2.25	SMA20	-8.19%	SMA50	-23.41%	SMA200	-7.73%	Volume	2,063,351	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Today 09:15AM	Is Recursion Pharmaceuticals Stock a Buy? (Motley Fool)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-22-23 05:05PM	Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend (InvestorPlace)
05:50AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too (Motley Fool)
Sep-15-23 11:15AM	Insider Sell: CFO Michael Secora Sells 50,000 Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
10:07AM	Loading…
10:07AM	Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics (Motley Fool)
08:45AM	3 AI Drug Discovery Stocks to Watch (Motley Fool)
Sep-12-23 10:09AM	Cathie Wood Pours Millions Into These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back Heres Why You Should Take Notice (TipRanks)
05:14AM	2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street (Motley Fool)
Sep-11-23 09:35AM	Where Will Recursion Pharmaceuticals Be in 3 Years? (Motley Fool)
Sep-08-23 09:07PM	CEO Christopher Gibson Sells 58,765 Shares of Recursion Pharmaceuticals Inc (RXRX) (GuruFocus.com)
Sep-06-23 06:17AM	2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street (Motley Fool)
Sep-05-23 06:35PM	3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains (InvestorPlace)
04:30PM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
12:44PM	AI investment in health care to jump in 2024: Morgan Stanley (Yahoo Finance Video)
07:59AM	Loading…
07:59AM	Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection (GlobeNewswire)
Aug-25-23 05:10AM	Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe (Motley Fool)
Aug-24-23 10:29AM	Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks (Motley Fool) -8.64%
Aug-21-23 07:43PM	Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now (InvestorPlace)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-11-23 09:53AM	3 Things About Recursion Pharmaceuticals That Smart Investors Know (Motley Fool)
Aug-08-23 03:06PM	3 AI Stocks Youll Regret Not Buying Soon (InvestorPlace)
09:40AM	Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	Recursion Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
08:00AM	Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds (GlobeNewswire)
07:58AM	Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 07:45AM	2 Healthcare AI Stocks That Could Go Parabolic (Motley Fool)
Aug-01-23 08:30AM	Recursion to Participate in Upcoming Investor Conference (GlobeNewswire)
Jul-26-23 06:58PM	Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships (GlobeNewswire) -7.03%
04:24PM	Biotech Stocks Join AI-Fueled Rally (The Wall Street Journal)
10:07AM	Loading…
Jul-21-23 10:07AM	3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other (Motley Fool)
Jul-19-23 02:18PM	Rebel's Edge - July 19: $CVNA, $SCHW, $RXRX, and Shohei Ohtani (TheStreet.com) +16.36%
06:30AM	Why It May Not Be Too Late to Join Nvidias Sky-High AI Rally (InvestorPlace)
Jul-18-23 10:00AM	Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals (Motley Fool)
06:27AM	Nvidia Just Invested $50 Million in This Biotech -- Should You Buy It? (Motley Fool)
06:26AM	NVDA Stock Update: What Nvidia Investors Need to Be Watching Now (InvestorPlace)
Jul-14-23 11:53AM	3 Biotech Stocks Using AI to Change Healthcare Forever (InvestorPlace)
05:51AM	Why Recursion Pharmaceuticals Stock Is Skyrocketing This Week (Hint: Thanks, Nvidia) (Motley Fool)
Jul-13-23 11:01AM	Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery (Zacks)
06:53AM	A Look At The Intrinsic Value Of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) (Simply Wall St.)
Jul-12-23 04:15PM	AI Drug Discovery Firm Recursion Surges Following $50 Million Nvidia Investment (Bloomberg) +78.17%
04:04PM	Recursion Catapults 78% On Nvidia Investment For AI In Drug Development (Investor's Business Daily)
02:39PM	Rebel's Edge - July 12: $UPS, $LCID, $RXRX, and MLB Locks & Sleepers (TheStreet.com)
02:18PM	Recursion Stock Soars After Nvidia Invests $50 Million for AI Drug Discovery (Barrons.com)
02:04PM	Recursion Pharmaceuticals Stock Surges On Nvidia Investment (The Wall Street Journal)
12:07PM	Why Shares of Recursion Pharmaceuticals Are Skyrocketing Wednesday (Motley Fool)
08:30AM	Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery (GlobeNewswire)
Jun-29-23 05:13AM	Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now (InvestorPlace)
Jun-26-23 11:48AM	Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem (GlobeNewswire)
Jun-13-23 08:00AM	Recursions Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled (GlobeNewswire)
Jun-01-23 08:30AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-29-23 08:45AM	Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth Buying (Motley Fool)
May-25-23 04:00PM	Altitude Lab Relocates to Gateways BioHive Hub (GlobeNewswire)
May-16-23 08:30AM	Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -8.39%
May-09-23 11:08AM	Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 11% (Simply Wall St.)
May-08-23 09:25AM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +8.53%
08:18AM	Recursion Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
08:14AM	Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results (GlobeNewswire)
07:59AM	Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities (GlobeNewswire)
May-02-23 08:30AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-13-23 06:35AM	Recursion Pharmaceuticals (NASDAQ:RXRX shareholders incur further losses as stock declines 4.7% this week, taking one-year losses to 20% (Simply Wall St.) +6.50%
Apr-03-23 08:30AM	Recursion to Participate in Upcoming Investor Conference (GlobeNewswire)
Mar-28-23 04:14PM	Recursion Publishes Second Annual Environmental, Social and Governance Report (GlobeNewswire)
03:57PM	Top 10 Growth Stocks in Biotech (Insider Monkey)
Mar-10-23 09:24AM	Too Cheap to Ignore: Cathie Wood Snaps Up These 2 Stocks Under $10 (TipRanks) -5.73%
Mar-01-23 08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
05:27AM	Here's Why We're Not At All Concerned With Recursion Pharmaceuticals' (NASDAQ:RXRX) Cash Burn Situation (Simply Wall St.)
Feb-27-23 07:55PM	Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-21-23 11:00AM	Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare Diseases (GlobeNewswire)
Feb-01-23 08:01AM	Recursion to Participate in Upcoming Investor Conference (PR Newswire)
Jan-27-23 09:55AM	Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' Now (Zacks)
Jan-26-23 08:30AM	Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day (PR Newswire)
Jan-25-23 12:00PM	Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67% (Zacks)
Dec-28-22 05:04AM	Institutional investors may adopt severe steps after Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) latest 7.4% drop adds to a year losses (Simply Wall St.)
Dec-20-22 07:55AM	Recursion to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-17-22 05:04AM	Forecast: Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Business Prospects Have Improved Drastically (Simply Wall St.)
Nov-10-22 05:42AM	Recursion Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) +8.50%
Nov-08-22 07:05PM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-02-22 09:54AM	Harvard University Stock Portfolio: Top 10 Picks (Insider Monkey)
07:59AM	Recursion to Participate in Upcoming Investor Conferences (PR Newswire)
Oct-28-22 03:04PM	Recursion Pharmaceuticals Puts Strength on Full Display (TheStreet.com)
Oct-25-22 08:00AM	Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB (PR Newswire)
Oct-20-22 03:17PM	Shareholders in Recursion Pharmaceuticals (NASDAQ:RXRX) have lost 46%, as stock drops 7.9% this past week (Simply Wall St.)
Sep-29-22 06:54AM	Is Recursion Pharmaceuticals (RXRX) a Worthy Investment? (Insider Monkey) -7.89%
Sep-13-22 07:59AM	Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022 (PR Newswire)
Sep-04-22 10:36AM	These 3 Stocks Are the Future of Biotechnology (Motley Fool)
Sep-01-22 07:55AM	Recursion to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-18-22 07:55AM	Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum (PR Newswire) -6.51%
Aug-13-22 08:05AM	Earnings Update: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported And Analysts Are Boosting Their Estimates (Simply Wall St.)
Aug-09-22 06:15PM	Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.77%
04:15PM	Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results (PR Newswire)
Aug-02-22 07:55AM	Recursion to Participate in Upcoming Investor Conference (PR Newswire) +6.14%
Jul-28-22 03:40PM	Cathie Woods Top 10 Buys in July (Insider Monkey)
Jul-21-22 07:55AM	Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis (PR Newswire) -5.56%
Jul-10-22 06:30AM	3 Amazing Stocks Under $10 (Motley Fool)
Jun-21-22 10:20AM	Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth (Simply Wall St.) +9.97%
Jun-20-22 07:55AM	Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference (PR Newswire)
Jun-04-22 09:00AM	3 Cathie Wood Stocks That Could Deliver Monster Returns (Motley Fool)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Borgeson Blake	Director	Sep 19	Sale	8.36	8,885	74,278	7,442,960	Sep 21 06:35 PM
Virani Shafique	Chief Business Officer	Sep 15	Option Exercise	2.22	18,000	39,960	158,351	Sep 19 05:50 PM
Virani Shafique	Chief Business Officer	Sep 15	Sale	8.66	18,000	155,880	140,351	Sep 19 05:50 PM
Secora Michael	Chief Financial Officer	Sep 13	Option Exercise	2.22	37,500	83,250	913,186	Sep 14 06:26 PM
Secora Michael	Chief Financial Officer	Sep 13	Sale	8.69	25,000	217,318	888,186	Sep 14 06:26 PM
Secora Michael	Chief Financial Officer	Sep 12	Option Exercise	2.22	37,500	83,250	900,686	Sep 14 06:26 PM
Secora Michael	Chief Financial Officer	Sep 12	Sale	8.43	25,000	210,632	875,686	Sep 14 06:26 PM
Gibson Christopher	Chief Executive Officer	Sep 06	Option Exercise	2.48	31,250	77,500	905,056	Sep 08 05:01 PM
Gibson Christopher	Chief Executive Officer	Sep 06	Sale	8.78	33,765	296,575	871,291	Sep 08 05:01 PM
Gibson Christopher	Chief Executive Officer	Sep 06	Sale	8.83	25,000	220,867	0	Sep 08 05:01 PM
Borgeson Blake	Director	Sep 05	Sale	8.79	8,885	78,136	7,451,845	Sep 07 07:02 PM
Larson Tina Marriott	President and COO	Aug 24	Option Exercise	1.06	3,000	3,180	421,782	Aug 28 06:04 PM
Larson Tina Marriott	President and COO	Aug 24	Sale	8.66	3,000	25,968	418,782	Aug 28 06:04 PM
Borgeson Blake	Director	Aug 22	Sale	8.91	8,885	79,181	7,460,730	Aug 24 05:51 PM
Secora Michael	Chief Financial Officer	Aug 16	Option Exercise	2.22	37,500	83,250	888,186	Aug 17 06:35 PM
Secora Michael	Chief Financial Officer	Aug 16	Sale	8.90	25,000	222,518	863,186	Aug 17 06:35 PM
Secora Michael	Chief Financial Officer	Aug 15	Option Exercise	2.22	37,500	83,250	875,686	Aug 17 06:35 PM
Virani Shafique	Chief Business Officer	Aug 15	Option Exercise	2.22	18,000	39,960	158,351	Aug 17 06:39 PM
Secora Michael	Chief Financial Officer	Aug 15	Sale	9.27	25,000	231,792	850,686	Aug 17 06:35 PM
Virani Shafique	Chief Business Officer	Aug 15	Sale	9.25	18,000	166,500	140,351	Aug 17 06:39 PM
Borgeson Blake	Director	Aug 08	Sale	11.16	17,770	198,283	7,469,615	Aug 10 05:33 PM
Gibson Christopher	Chief Executive Officer	Aug 02	Option Exercise	4.42	39,924	176,384	955,734	Aug 04 05:51 PM
Gibson Christopher	Chief Executive Officer	Aug 02	Sale	13.04	65,015	847,712	890,719	Aug 04 05:51 PM
Larson Tina Marriott	President and COO	Jul 27	Option Exercise	1.06	8,000	8,480	432,160	Jul 28 05:50 PM
Larson Tina Marriott	President and COO	Jul 27	Sale	13.62	8,000	108,994	424,160	Jul 28 05:50 PM
Virani Shafique	Chief Business Officer	Jul 26	Option Exercise	2.22	20,000	44,400	163,954	Jul 27 06:31 PM
Virani Shafique	Chief Business Officer	Jul 26	Sale	14.41	20,000	288,200	143,954	Jul 27 06:31 PM
Virani Shafique	Chief Business Officer	Jul 25	Option Exercise	2.22	20,000	44,400	163,954	Jul 27 06:31 PM
Virani Shafique	Chief Business Officer	Jul 25	Sale	14.30	20,000	286,000	143,954	Jul 27 06:31 PM
Borgeson Blake	Director	Jul 25	Sale	14.61	18,719	273,464	7,487,385	Jul 27 06:30 PM
Secora Michael	Chief Financial Officer	Jul 19	Option Exercise	2.22	37,500	83,250	867,913	Jul 19 07:07 PM
Secora Michael	Chief Financial Officer	Jul 19	Sale	15.53	25,000	388,348	842,913	Jul 19 07:07 PM
Secora Michael	Chief Financial Officer	Jul 18	Option Exercise	2.22	37,500	83,250	855,413	Jul 19 07:07 PM
Virani Shafique	Chief Business Officer	Jul 18	Option Exercise	2.22	30,000	66,600	173,954	Jul 19 07:01 PM
Virani Shafique	Chief Business Officer	Jul 18	Sale	13.74	30,000	412,200	143,954	Jul 19 07:01 PM
Secora Michael	Chief Financial Officer	Jul 18	Sale	13.63	25,000	340,802	830,413	Jul 19 07:07 PM
Virani Shafique	Chief Business Officer	Jul 17	Option Exercise	2.22	30,000	66,600	173,954	Jul 19 07:01 PM
Virani Shafique	Chief Business Officer	Jul 17	Sale	11.72	30,000	351,600	143,954	Jul 19 07:01 PM
Burrell Terry-Ann	Director	Jul 13	Sale	12.59	8,275	104,143	54,847	Jul 14 06:52 PM
Gibson Christopher	Chief Executive Officer	Jul 12	Option Exercise	2.48	31,250	77,500	947,628	Jul 14 06:52 PM
Burrell Terry-Ann	Director	Jul 12	Sale	12.03	108,725	1,308,271	63,122	Jul 14 06:52 PM
Gibson Christopher	Chief Executive Officer	Jul 12	Sale	13.14	31,818	417,976	915,810	Jul 14 06:52 PM
Gibson Christopher	Chief Executive Officer	Jul 12	Sale	11.77	25,000	294,266	0	Jul 14 06:52 PM
Borgeson Blake	Director	Jul 11	Sale	6.89	8,885	61,194	7,520,104	Jul 13 04:54 PM
Larson Tina Marriott	President and COO	Jun 29	Option Exercise	1.06	3,000	3,180	427,160	Jul 03 03:21 PM
Larson Tina Marriott	President and COO	Jun 29	Sale	7.49	3,000	22,470	424,160	Jul 03 03:21 PM
Borgeson Blake	Director	Jun 27	Sale	7.39	8,885	65,639	7,528,989	Jun 29 05:57 PM
Secora Michael	Chief Financial Officer	Jun 14	Option Exercise	2.22	37,500	83,250	842,913	Jun 15 07:28 PM
Secora Michael	Chief Financial Officer	Jun 14	Sale	10.07	25,000	251,837	817,913	Jun 15 07:28 PM
Secora Michael	Chief Financial Officer	Jun 13	Option Exercise	2.22	37,500	83,250	830,413	Jun 15 07:28 PM
Secora Michael	Chief Financial Officer	Jun 13	Sale	9.93	25,000	248,308	805,413	Jun 15 07:28 PM
Borgeson Blake	Director	Jun 13	Sale	9.98	15,485	154,506	7,525,262	Jun 15 07:30 PM
Gibson Christopher	Chief Executive Officer	Jun 07	Option Exercise	2.48	31,250	77,500	972,814	Jun 09 05:12 PM
Gibson Christopher	Chief Executive Officer	Jun 07	Sale	9.05	56,436	510,808	916,378	Jun 09 05:12 PM
Virani Shafique	Chief Business Officer	Jun 02	Sale	8.93	17,865	159,534	143,954	Jun 05 06:29 PM
Virani Shafique	Chief Business Officer	Jun 01	Sale	8.58	25,000	214,500	161,819	Jun 05 06:29 PM
Larson Tina Marriott	President and COO	May 31	Option Exercise	1.06	3,000	3,180	427,160	Jun 02 06:05 PM
Larson Tina Marriott	President and COO	May 31	Sale	8.63	3,000	25,888	424,160	Jun 02 06:05 PM
Borgeson Blake	Director	May 30	Sale	8.79	8,885	78,134	7,540,747	Jun 01 05:41 PM
Borgeson Blake	Director	May 16	Sale	5.09	8,885	45,241	7,549,632	May 17 06:22 PM
Gibson Christopher	Chief Executive Officer	May 03	Option Exercise	2.48	31,250	77,500	986,298	May 05 06:44 PM
Gibson Christopher	Chief Executive Officer	May 03	Sale	4.71	33,073	155,761	953,225	May 05 06:44 PM
Gibson Christopher	Chief Executive Officer	May 03	Sale	4.90	25,000	122,574	0	May 05 06:44 PM
Borgeson Blake	Director	Apr 18	Sale	5.93	8,885	52,730	7,558,517	Apr 20 05:37 PM
Gibson Christopher	Chief Executive Officer	Apr 06	Sale	6.64	40,000	265,672	906,710	Apr 07 05:30 PM
Gibson Christopher	Chief Executive Officer	Apr 05	Option Exercise	2.48	31,250	77,500	960,037	Apr 07 05:30 PM
Gibson Christopher	Chief Executive Officer	Apr 05	Sale	6.46	13,327	86,038	946,710	Apr 07 05:30 PM
Borgeson Blake	Director	Apr 04	Sale	6.53	8,885	57,992	7,567,402	Apr 06 05:38 PM
Borgeson Blake	Director	Mar 21	Sale	7.40	8,885	65,744	7,576,287	Mar 23 05:07 PM
Gibson Christopher	Chief Executive Officer	Mar 09	Sale	7.77	15,000	116,620	938,787	Mar 10 05:34 PM
Gibson Christopher	Chief Executive Officer	Mar 08	Option Exercise	2.48	93,750	232,500	1,034,677	Mar 10 05:34 PM
Gibson Christopher	Chief Executive Officer	Mar 08	Sale	8.10	70,890	573,925	963,787	Mar 10 05:34 PM
Gibson Christopher	Chief Executive Officer	Mar 08	Sale	8.09	25,000	202,348	0	Mar 10 05:34 PM
Borgeson Blake	Director	Mar 07	Sale	8.33	8,885	73,989	7,585,172	Mar 09 05:36 PM
Gibson Christopher	Chief Executive Officer	Mar 02	Sale	7.92	18,500	146,502	940,927	Mar 06 06:07 PM
Gibson Christopher	Chief Executive Officer	Mar 02	Sale	7.91	2,500	19,767	0	Mar 06 06:07 PM
Mubadala Investment Co PJSC	10% Owner	Mar 01	Buy	7.94	48,867	388,082	12,919,105	Mar 02 04:05 PM
Mubadala Investment Co PJSC	10% Owner	Feb 28	Buy	7.97	815	6,496	12,870,238	Mar 01 04:06 PM
Mubadala Investment Co PJSC	10% Owner	Feb 27	Buy	7.69	52,500	403,725	12,869,423	Feb 28 04:14 PM
Mubadala Investment Co PJSC	10% Owner	Feb 24	Buy	7.64	109,118	833,552	12,816,923	Feb 27 04:06 PM
Larson Tina Marriott	President and COO	Feb 23	Option Exercise	1.06	8,000	8,480	435,844	Feb 27 05:46 PM
Mubadala Investment Co PJSC	10% Owner	Feb 23	Buy	7.79	51,864	403,792	12,707,805	Feb 24 04:08 PM
Larson Tina Marriott	President and COO	Feb 23	Sale	7.82	8,000	62,540	427,844	Feb 27 05:46 PM
Mubadala Investment Co PJSC	10% Owner	Feb 22	Buy	7.83	50,941	399,016	12,655,941	Feb 23 04:26 PM
Mubadala Investment Co PJSC	10% Owner	Feb 21	Buy	7.74	94,418	731,126	12,605,000	Feb 22 04:07 PM
Borgeson Blake	Director	Feb 21	Sale	7.73	8,885	68,708	7,594,057	Feb 23 05:48 PM
Mubadala Investment Co PJSC	10% Owner	Feb 17	Buy	7.71	63,382	488,986	12,510,582	Feb 21 04:07 PM
Mubadala Investment Co PJSC	10% Owner	Feb 16	Buy	7.90	42,682	337,043	12,447,200	Feb 17 05:27 PM
Virani Shafique	Chief Business Officer	Feb 16	Sale	8.42	1,768	14,887	187,332	Feb 17 05:13 PM
Virani Shafique	Chief Business Officer	Feb 15	Option Exercise	2.22	7,486	16,619	197,332	Feb 17 05:13 PM
Virani Shafique	Chief Business Officer	Feb 15	Sale	8.33	7,486	62,358	189,846	Feb 17 05:13 PM
Mubadala Investment Co PJSC	10% Owner	Feb 14	Buy	7.95	6,300	50,060	12,404,518	Feb 15 04:06 PM
Mubadala Investment Co PJSC	10% Owner	Feb 13	Buy	7.97	32,474	258,837	12,398,218	Feb 14 04:10 PM
Mubadala Investment Co PJSC	10% Owner	Feb 10	Buy	7.98	11,000	87,808	12,365,744	Feb 13 04:41 PM
Borgeson Blake	Director	Feb 07	Sale	8.81	8,885	78,263	7,602,942	Feb 09 04:53 PM
Gibson Christopher	Chief Executive Officer	Feb 02	Sale	9.22	18,500	170,548	942,273	Feb 03 05:11 PM
Gibson Christopher	Chief Executive Officer	Feb 02	Sale	9.21	2,500	23,013	0	Feb 03 05:11 PM
Mubadala Investment Co PJSC	10% Owner	Feb 01	Buy	7.97	600	4,782	12,354,744	Feb 02 04:07 PM
Larson Tina Marriott	President and COO	Jan 26	Option Exercise	1.06	8,000	8,480	211,654	Jan 27 05:03 PM
Mubadala Investment Co PJSC	10% Owner	Jan 26	Buy	7.99	7,886	63,006	12,354,144	Jan 27 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RXRX | Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience